MapLight Therapeutics Inc, a California-based clinical-stage biopharmaceutical company focused on treatment for debilitating central nervous system disorders, said on Monday that it has filed a registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) in connection with the commencement of a proposed initial public offering (IPO) of its common stock.

MapLight is offering 14,750,000 shares at an initial public offering price of USD17.00 per share. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 2,212,500 shares of common stock in connection with the proposed public offering. MapLight has applied to list its common stock for trading on the Nasdaq Global Market under the symbol 'MPLT'.

In addition to the shares proposed to be sold in the IPO, MapLight announced a proposed concurrent sale of 476,707 shares of common stock at the public offering price per share in a private placement to affiliates of Goldman Sachs & Co. The sale of the shares of common stock in the proposed private placement will not be registered under the Securities Act of 1933, as amended. The proposed private placement would close concurrently with, and be contingent and conditioned upon consummation of, the proposed IPO. However, the proposed IPO is not contingent on the consummation of the concurrent private placement.

MapLight has included in the registration statement the proposed public offering price and the number of shares offered and specific language under Rule 473(b) promulgated under the Securities Act of 1933, as amended, such that the registration statement is expected to become automatically effective 20 calendar days after the filing, or 26 October 2025, pursuant to Section 8(a) of the Securities Act. MapLight expects to complete the pricing of the proposed public offering on or after that date. If the federal government and the SEC resume normal operations prior to 26 October 2025, MapLight says that it will re-evaluate the use of Section 8(a) in connection with the proposed public offering.

Morgan Stanley, Jefferies, Leerink Partners and Stifel are acting as joint book-running managers for the proposed offering.